Appendix Table 4.

Sensitivity Analysis Excluding All Persons Enrolled in Medicare Part D and With a Medicare Physician Office Visit From the VA Cohort^*

Patients Using Brand-Name Drug	Oral Hypoglycemics, %	Insulin Analogues, %	Statins, %	ACE Inhibitors/ARBs, %
Patients excluded	10.8	11.0	10.5	10.2
VA original cohort	12.7	27.0	18.2	20.8
VA nondual user (sensitivity population)	12.8	26.3	18.3	20.6
VA dual users (excluded population)	11.8	33.0	17.8	22.1
Medicare cohort	35.3	75.1	50.7	42.5

ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; VA = Veterans Affairs.

^*“Medicare” refers to patients enrolled in fee-for-service Parts A and B and stand-alone Part D. “Statins” denotes 3-hydroxy-3-methyl coenzyme A reductase inhibitors. A total of 57 314 veterans (11% of the original VA cohort) were excluded.